ClinicalTrials.gg
RecruitingNCT06927947Updated Jun 15, 2026

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

An interventional study of Communication Intervention and Health Promotion and Education in Hereditary Malignant Neoplasm and Hereditary Neoplastic Syndrome, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
625
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.

Planned enrollment
9th of 18
625 · median 588
Started
2025
with 3 others
No phase
17 of 33
11 open now
Primary completion
2026-09
later than 0 of 18 live
Registered
27th of 33
by date
Lead sponsor
2 of 33
University of Michigan Rogel Cancer Center

Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 with no phase, reaches primary completion later than 0 of the 18 other live ones, and was the 27th registered.

Neoplastic Syndromes, Hereditary

47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.

Browse Neoplastic Syndromes, Hereditary studies →

Open to participants now

19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.

Read the detailed description

03JUN2025- Amendment was approved that shorten the study timeline from 12 to 6 months. We believe this is sufficient to capture our primary outcome (participation) and a shorter timeline may keep participants more engaged.

22MAY2026- Amendment was approved adjusting enrollment goals to account for new accrual of prospective probands and their relatives, and to clarify realistic expectations for relative enrollment numbers.

03

Conditions studied

  • Hereditary Malignant Neoplasm
  • Hereditary Neoplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome
  • PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic
  • PROBANDS: ≥ 18 years old
  • PROBANDS: Able to speak and read English
  • PROBANDS: Access to the internet
  • RELATIVES: Biological relative of proband
  • RELATIVES: ≥ 18 years old
  • RELATIVES: Able to speak and read English
  • RELATIVES: Access to the internet
  • RELATIVES: Have not completed germline genetic testing, per self-report at baseline

Exclusion criteria

Exclusion Criteria:

  • RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
625 participants (estimated)

Study arms

  • Experimental
    Prevention (Cascade Genetic Testing Platform)

    PROBANDS: Probands use the relative invitation tool to invite at-risk relatives to participate. RELATIVES: Participants receive access to the virtual Cascade Genetic Testing Platform, which includes a Genetic Testing Family Letter and access to the VGN. The Genetic Testing Family Letter provides information about the genetic diagnosis in the family, instructions for the relatives on how to schedule a genetic evaluation, and contact information for the U-M Cancer Genetics Clinic. The VGN is an interactive web-based tool that provides personalized information addressing readiness, barriers and motivators to testing, and knowledge, and presents educational content about genetic testing and information about testing options, including how to access them on study.

    Other: Communication Intervention · Other: Health Promotion and Education · Other: Informational Intervention · Other: Survey Administration

Interventions

  • OtherCommunication Intervention

    Use relative invitation tool

  • OtherHealth Promotion and Education

    Receive access to the VGN

  • OtherInformational Intervention

    Receive access to a Genetic Testing Family Letter

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Percentage of probands that utilize the invitation tool

    Will be defined as inviting at least 1 eligible at-risk relative. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

    Time frame: Up to 6 Months

  2. Percentage of invited relatives that engage

    Will be defined as enrolling in the study and accessing the informational content (letter and/or virtual genetics navigator) at least 1 time. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

    Time frame: Up to 6 Months

Secondary outcomes

  1. Extent of utilization of the invitation portal by probands

    Will be measured by the number of relatives invited out of the estimated number of eligible at-risk relatives (e.g. blood-related, have not completed genetic testing, living, 18 years or older). Will be calculated based on previously collected family records as reviewed by a genetic counselor, in conjunction with any updated information received from participants. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

    Time frame: Up to 6 Months

  2. Percentage of relatives invited who subsequently enroll in the study

    Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

    Time frame: Up to 6 Months

  3. Percentage of relative participants who have either scheduled or completed genetic testing

    Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

    Time frame: Up to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 15, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06927947
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Sep 23, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

MiGHT HelpLine
Contact
MiGHT-Cascade@med.umich.edu
(734) 764-4044
Elena M Stoffel
principal investigator · University of Michigan Rogel Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion